Pfizer, PhRMA back SOPA amid online protests

With dozens of websites blocked in protest of new anti-piracy legislation, Pfizer ($PFE) and PhRMA are among the intellectual-property champions that are lobbying for, rather than against, the proposed laws. Pfizer says the measures--one approved by the House, another by the Senate--would help prevent drug counterfeiting. Report

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.